The combined diabetic foot ulcer (DFU) and diabetic foot infection (DFI) market is set to triple in value from $292.1 million in 2015 to $873.4 million by 2025, representing a compound annual growth rate of 11.6%, according to research and consulting firm GlobalData.
The company’s latest report states that this relatively strong growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by a number of factors. These include the rising number of patients suffering from DFUs, the introduction of new drug Granexin, and an increased emphasis on the cost-effectiveness of advanced DFU treatments in preventing serious complications.
Jesus Cuaron, Ph.D., PPM, GlobalData’s Senior Analyst covering Cardiovascular and Metabolic Disorders, explains: “Generally speaking, the DFU market is expected to experience moderate changes over the next decade, with prospects for treatments entering the space looking bleak.
“Indeed, a number of wound-healing pipeline agents have recently failed clinical trials, primarily due to the lack of improved efficacy compared to current DFU standard-of-care practices, including products such as CytoTools’ DermaPro, an intralesional formulation of diperoxochloric acid, and Olympus Biotech’s topical trafermin spray. Overall, the development of novel DFU products has been very risky.”
The lack of approved and effective products to treat ischemic wounds opens an opportunity for any drug companies that can develop advanced wound therapies for this subset of the DFU population. However, to target the cause of ischemia, further understanding of the role of vascular disease in the development of DFUs will be necessary.
Cuaron continues: “Currently, FirstString’s Phase III candidate Granexin is the most promising drug in the DFU space. It statistically increases the rate of 100% wound closure compared to DFU standard of care. Specifically, patients on Granexin therapy saw significant healing occur within four to six weeks of first administration, whereas meaningful healing within the standard wound healing agent, Regranex, occurs at around 10 to 12 weeks.”
Despite positive safety reports, in terms of commercial attractiveness, FirstString will struggle due to a lack of experience in the wound care market. The company has, however, met with Relief Therapeutics, a company that aims to provide patients with treatments for diabetic neuropathy and sarcoidosis, with talk of an acquisition of the former by the latter.
“If FirstString is obtained by Relief Therapeutics, GlobalData believes the increased assets will substantially help with the development and marketing of Granexin, which promises to be an ideal therapy for helping heal DFUs safely and quickly,” the analyst concludes.
- Information based on GlobalData’s report Opportunity Analyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2025.